Skip to content
value.today

New Haven Pharmaceuticals, Inc.

🇺🇸 New Haven, Connecticut, USAPharmaceuticalsFounded 2008
Total raised
$18 M
2 rounds on record
Latest round
$12 M
Oct 2014
First round on record
Sep 2012
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of New Haven Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2014$12 MNo. 2$10 to $50 million

New Haven Pharmaceuticals, Inc.: Raise no. 2, Oct 2014

Investors in this round

9 investors had bought by the notice of Oct 23, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $22 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Penner, Jr. · Executive Officer, Director
  • Nancy Motola · Executive Officer
  • Patrick Fourteau · Executive Officer, Director
  • Daniel Wagner · Director
  • Larry Dillaha · Director
  • William Sessa · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harry Penner, Jr., Executive Chairman. Newest notice filed Oct 23, 2014. Read the notice at the SEC.

equitySEC
Sep 2012$6 MNo. 1$2 to $10 million

New Haven Pharmaceuticals, Inc.: Raise no. 1, Sep 2012

Investors in this round

17 investors had bought by the notice of Oct 2, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Harry Penner, Jr. · Executive Officer, Director, Promoter · """Promoter"" is selected as this related person is a founder of the issuer."
  • Nancy Motola · Executive Officer
  • Patrick Fourteau · Executive Officer, Director, Promoter · """Promoter"" is selected as this related person is a founder of the issuer."
  • Daniel Wagner · Director
  • Larry Dillaha · Director
  • William Sessa · Director
  • Rob Sterling · Promoter · """Promoter"" is selected as this related person is a founder of the issuer"
  • Scott Kozak · Promoter · """Promoter"" is selected as this related person is a founder of the issuer."

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Harry H. Penner, Jr., Executive Chairman. Newest notice filed Oct 2, 2012. Read the notice at the SEC.

equity, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • New Haven Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2014).

    SEC Form D · Oct 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of New Haven Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by New Haven Pharmaceuticals, Inc.
NameRoleNamed in
Harry Penner, Jr.Executive officerOct 2014
Nancy MotolaExecutive officerOct 2014
Patrick FourteauExecutive officerOct 2014
Daniel WagnerDirectorOct 2014
Harry Penner, Jr.DirectorOct 2014
Larry DillahaDirectorOct 2014
Patrick FourteauDirectorOct 2014
William SessaDirectorOct 2014
Harry Penner, Jr."""Promoter"" is selected as this related person is a founder of the issuer."Oct 2012
Patrick Fourteau"""Promoter"" is selected as this related person is a founder of the issuer."Oct 2012
Rob Sterling"""Promoter"" is selected as this related person is a founder of the issuer"Oct 2012
Scott Kozak"""Promoter"" is selected as this related person is a founder of the issuer."Oct 2012